Tyligand Bioscience Ltd. has patented GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Astrazeneca AB has synthesized nicotinamide N-methyltransferase (NNMT) inhibitors reported to be useful for the treatment of chronic kidney disease, acute kidney injury and diabetic nephropathy.

Haisco Pharmaceutical Group Co. Ltd. has prepared and tested glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes and obesity.

Animol Discovery Inc. has prepared and tested cyclic depsipeptides reported to be useful for the treatment of parasitic infections.

Wavebreak Therapeutics LLC has identified thiazole compounds acting as α-synuclein (SNCA) aggregation inhibitors reported to be useful for the treatment of amyloidosis, Creutzfeldt-Jakob disease, frontotemporal dementia, Gaucher disease, Lewy body dementia, multiple system atrophy, progressive supranuclear palsy and Parkinson’s disease, among others.

Systimmune Inc. has synthesized antibody-drug conjugates comprising antibodies targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to cytotoxic drugs through linker reported to be useful for the treatment of cancer.

Vrise Therapeutics Inc. has discovered ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Erasca Inc. has described GTPase KRAS (G12D mutant) and/or KRAS (G12V mutant) inhibitors reported to be useful for the treatment of cancer.

Flare Therapeutics Inc. has disclosed cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.

Bristol Myers Squibb Co. has prepared and tested proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety through a linker reported to be useful for the treatment of autoimmune diseases and inflammatory disorders.